A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass ...

The condition is better measured by looking at factors like inflammation, insulin resistance, and glucose tolerance, ...

CCT-217 represents a paradigm shift in obesity treatment through its revolutionary approach. Breakthrough Preclinical Results: 26-34% total weight loss achieved through selective fat mass ...

Eli Lilly, a leading US pharmaceutical company, is gearing up to launch its groundbreaking diabetes and obesity medication, Tirzepatide—commercially known as Mounjaro—in India by 2025.

CCT-217 represents a paradigm shift in obesity treatment through its revolutionary approach. "CCT-217's unique dual-mechanism approach represents a fundamental advancement in obesity treatment ...